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Abstract
Background: There is evidence from epidemiological and in vitro studies that the biological effects of testosterone
(T) on cell cycle and survival are modulated by 1,25-dihydroxyvitamin D3 (1,25(OH)2D3) in prostate cancer. To
investigate the cross talk between androgen- and vitamin D-mediated intracellular signaling pathways, the
individual and combined effects of T and 1,25(OH)2D3 on global gene expression in LNCaP prostate cancer cells
were assessed.
Results: Stringent statistical analysis identifies a cohort of genes that lack one or both androgen response
elements (AREs) or vitamin D response elements (VDREs) in their promoters, which are nevertheless differentially
regulated by both steroids (either additively or synergistically). This suggests that mechanisms in addition to VDR-
and AR-mediated transcription are responsible for the modulation of gene expression. Microarray analysis shows
that fifteen miRNAs are also differentially regulated by 1,25(OH)2D3 and T. Among these miR-22, miR-29ab, miR-134,
miR-1207-5p and miR-371-5p are up regulated, while miR-17 and miR-20a, members of the miR-17/92 cluster are
down regulated. A number of genes implicated in cell cycle progression, lipid synthesis and accumulation and
calcium homeostasis are among the mRNA targets of these miRNAs. Thus, in addition to their well characterized
effects on transcription, mediated by either or both cognate nuclear receptors, 1,25(OH)2D3 and T regulate the
steady state mRNA levels by modulating miRNA-mediated mRNA degradation, generating attenuation feedback
loops that result in global changes in mRNA and protein levels. Changes in genes involved in calcium homeostasis
may have specific clinical importance since the second messenger Ca
2+ is known to modulate various cellular
processes, including cell proliferation, cell death and cell motility, which affects prostate cancer tumor progression
and responsiveness to therapy.
Conclusions: These data indicate that these two hormones combine to drive a differentiated phenotype, and
reinforce the idea that the age dependent decline in both hormones results in the de-differentiation of prostate
tumor cells, which results in increased proliferation, motility and invasion common to aggressive tumors. These
studies also reinforce the potential importance of miRNAs in prostate cancer progression and therapeutic
outcomes.
Background
Prostate cancer is the most commonly diagnosed non-
cutaneous cancer in American males and is the second
leading cause of cancer-related deaths in males in North
America [1]. Androgens, including testosterone (T) and
its active metabolite 5a-dihydrotestosterone (5a-DHT),
are important for the development and growth of early
stage prostate tumors and exert their effects via andro-
gen receptor (AR) [2-4]. Androgen ablation has been
one of the mainstays for the treatment of early stage,
organ-confined prostate cancer along with surgery and
radiation therapy.
Several epidemiological studies have suggested that
adequate levels of vitamin D are critical for the preven-
tion of various solid tumors, including breast, ovarian
and colon cancers [5,6]. The risk of developing and
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any medium, provided the original work is properly cited.dying of these cancers appears to be inversely correlated
with sun exposure, and/or vitamin D status, suggesting
that vitamin D has chemopreventive properties [7].
Some studies have also suggested that vitamin D may
p l a yar o l ei np r o s t a t ec a n c e rp r e v e n t i o n[ 8 , 9 ] ,b u tt h e
data are less convincing than in other tumors and sev-
eral recent meta-analyses have found weak or no asso-
ciations between serum 25-hydroxyvitamin D3 (25(OH)
2D3) levels and tumor incidence and progression
[10-13]. In addition, the effects of 1,25(OH)2D3 on
tumor growth in the TRAMP, LPB-Tag transgenic and
Nkx3.1;PTEN mutant mouse models of prostate cancer
have produced conflicting results [14-16]. However, a
variety of in vitro studies demonstrate that 1,25(OH)2D3
or its non-calcemic analogs (EB1089; CB 1093; Gemini
analogs) induce apoptosis in a variety of prostate cancer
cell lines including LNCaP, LNCaP C4-2, ALVA-3,
LAPC-4, DU-145 and PC-3 [17-20]. These effects appear
to occur through a combination of G0/G1 cell cycle
arrest, apoptosis, differentiation and inhibition of angio-
genesis [21-25]. In contrast, other studies have shown
that 1,25(OH)2D3 induces cell cycle arrest but not apop-
tosis [26-28]. These disparate effects of 1,25(OH)2D3 on
prostate tumor biology appear to be dictated predomi-
nantly by the androgen status of the mice [16] or the
level of androgen in the culture medium [17,29], sug-
gesting that in prostate cancer, there may be significant
cross talk between androgen-mediated growth and vita-
min D3-mediated cell cycle arrest and differentiation
which may influence tumor initiation and progression,
and impact tumor growth and affect subsequent thera-
peutic intervention [17].
MicroRNAs (miRNAs) are a class of small non-coding,
single-stranded RNAs that post-transcriptionally modu-
late the steady state levels of mRNA by targeting the 3’
untranslated regions (3’UTR) of mRNAs. Recent studies
h a v ef o u n dt h a ta b e r r a n tm i R N Ae x p r e s s i o ni sc l o s e l y
associated with prostate cancer initiation and progression
[30,31]. Several miRNAs that possess either oncogenic
(miR-221/222, miR-21, miR-125b) [32-36] or tumor sup-
pressor roles (miR-34 cluster, miR-146a, miR-200c)
[37,38] have been identified in prostate cancer and some
of these are associated with the castration resistant phe-
notype [34], or hormone-independent growth of prostate
cancer [33]. Neither the effect of 1,25(OH)2D3 on
miRNA levels in prostate cancer cell lines, nor the inter-
action with androgen signaling to modulate mRNA and
miRNA transcription have been investigated. However,
the importance of a regulatory loop involving miR-106b
and p21 mRNA which is modulated by 1,25(OH)2D3 in
non malignant prostate cells has recently been described
[39]. The experiments described in this manuscript
examine effects of testosterone and 1,25(OH)2D3,a d m i -
nistered alone or in combination, on the mRNA and
miRNA expression in LNCaP cells and demonstrate that
cross talk between VDR- and AR-mediated signaling sig-
nificantly influences the biology of prostate cancer cells.
Using concurrent microarray analyses in LNCaP cells of
both miRNA and mRNA, we have found that androgen-
mediated transcription of both mRNA and miRNA is
enhanced by 1,25(OH)2D3, either additively or synergisti-
cally, highlighting the extensive cross talk between the
two receptors. Many of the gene targets of T and 1,25
(OH)2D3 have significant clinical relevance. The data
demonstrate that while androgens may play a central role
in the development of prostate cancer, declining T levels
common in older patients may play a significant role in
tumor progression, particularly in patients who are also
vitamin D deficient.
Results
Biological Response of LNCaP cells to T and 1,25(OH)2D3
1,25(OH)2D3 has variously been reported to induce G0/
G1 cell cycle arrest or apoptosis in androgen-responsive
LNCaP cells and other cell lines. In our hands, 100 nM
1,25(OH)2D3 and 5 nM T alone reduce growth of
LNCaP cells as measured by crystal violet staining (Fig-
ure 1A). This correlates to the induction of G0/G1 cell
cycle arrest in LNCaP cells (Figure 1B) with no evidence
of apoptosis (Figure 1C). The combination of T and
1,25(OH)2D3 attenuates cell growth to a greater extent
than either treatment alone (Figure 1A), which corre-
lates to the nearly synchronous arrest of the cell popula-
tions in the G0/G1 phase of the cell cycle (Figure 1B).
There was no evidence of cell death in LNCaP cells
after treatment with 1,25(OH)2D3 alone or in combina-
tion with T, as monitored by changes in the sub G0
population after staining with propidium iodide (not
shown) or DNA fragmentation as measured by Apo-
BrdU (Figure 1C). The lack of apoptosis in these cells is
not due to defects in the apoptotic machinery, since
bicalutamide induces apoptosis in LNCaP cells both in
the absence and presence of T and 1,25(OH)2D3 (Figure
1C). The effects of T and 1,25(OH)2D3 on these para-
meters have been characterized at earlier and later time
points with similar results (results not shown). These
data demonstrate that AR- and VDR-mediated intracel-
lular signaling pathways cooperate to modulate cell
cycle kinetics in prostate cancer cells and attenuate their
growth and proliferation without directly affecting apop-
tosis. They also demonstrate that the combination of T
and 1,25(OH)2D3 does not block the sensitivity of the
cells to bicalutamide.
Effect of T and 1,25(OH)2D3 on gene expression in LNCaP
cells
Total RNA samples obtained from LNCaP cells treated
for 48 h with 5 nM T and 100 nM 1,25(OH)2D3 alone
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Page 2 of 15or in combination were interrogated with Nimblegen-
HG18-4plex whole genome microarrays. Gene expres-
sion profiles were clustered based on gene entities and
treatment conditions. Treatment with T or 1,25(OH)2D3
alone and in combination shows distinct expression pat-
terns that are tightly clustered by their treatment groups
(Figure 2A). After filtering for the number of positive
probes per gene, statistical analysis on the microarray
array data with 1.5 fold cut-off generates a gene list that
contains 1127 gene entities that are modulated by either
T (326) or 1,25(OH)2D3 (825) or both additively (280)
in LNCaP cells. Omnibus testing demonstrates that the
effect of T and D on the expression of these genes is
highly significant (p < 0.0001). Many of the 825 genes
regulated by 1,25(OH)2D3,i d e n t i f i e di nt h i sa r r a yh a v e
been identified as vitamin D responsive genes in other
studies [40-42]. Approximately 65% of T modulated
genes (202 of 326) has been previously reported to be
responsive to androgens (T, 5a-dihydrotestosterone or
R1881) in other in vitro systems (Androgen Responsive
Gene Database: http://argdb.fudan.edu.cn). Thus, addi-
tion of exogenous T to the medium of LNCaP cells
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Figure 1 The effect of T and 1,25(OH)2D3 alone and in combination on LNCaP cells. LNCaP cells were plated as described in Material and
Methods, and treated with 5 nM T and 100 nM 1,25(OH)2D3 alone or in combination for the indicated times (Panel A) or 48 h (panels B and C).
Panel A: changes in cell number were measured by crystal violet; Panel B: cell cycle kinetics were measured by flow cytometry using propidium
iodide staining (Blue:G0/G1 phase, Red: S phase; Black G2/M); Panel C: Cell death was monitored by flow cytometry of Apo-BrdU incorporation as
described in Experimental Procedures [(Apoptotic cells shown upper right quadrant (Q2)]. LNCaP cells were also treated with bicalutamide in the
absence and presence of T and 1,25(OH)2D3 for 48 h.
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Page 3 of 15identifies a significant new cohort of 124 mRNAs that
are androgen responsive. Furthermore, T and 1,25(OH)
2D3 also synergistically modulate 256 genes that are not
significantly regulated by either hormone alone, and
thus form a nonintersecting dataset (Figure 2B). These
d a t as u g g e s tA Ra n dV D Rs h a r em a n yc o m m o ng e n e
targets and cooperate to regulate cellular processes in
LNCaP cells.
Gene Set Enrichment Analysis using Pathways Studio
and Gene Ontology analysis from DAVID Bioinfor-
matics Resources (NIAID) were used to assess the
significance of the interactions between T and 1,25(OH)
2D3 in LNCaP cells. As shown in Table 1, T alone sig-
nificantly affects processes associated with cell division
(particularly mitosis), microtubule based movement,
chromosome segregation and progression through ana-
phase in LNCaP cells. 1,25(OH)2D3 alone also signifi-
cantly affects the expression of genes associated with
these cellular processes, in addition to those involved in
calcium ion homeostasis and phosphoinositide-mediated
signaling. Treatment with T and 1,25(OH)2D3 enhances
the response of genes associated with these ontologies,
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Figure 2 The effect of T and 1,25(OH)2D3 on mRNA expression in LNCaP cells. LNCaP cells were plated as described in Material and
Methods, and treated with 5 nM T and 100 nM 1,25(OH)2D3 alone or in combination for 48 h. Total RNA was extracted and interrogated on
Nimblegen-HG18-4plex arrays. Three independent replicates of each treatment were used for the analysis. Panel A: hierarchical clustering of the
expression array data using the GeneSpring GX10 software. Panel B: Venn diagram analysis of the microarray data (Green: 1,25(OH)2D3-moduated,
Orange: T-modulated, Blue: synergistically modulated genes by T and 1,25(OH)2D3. Panel C: Analysis of Selected Gene Ontologies Modulated by T
and 1,25(OH)2D3 in LNCaP Cells. Functional annotation of each gene was assigned based on DAVID Bioinformatics Resources 2008 (NIAID).
Magenta: gene up regulated by treatment; Green: down regulated by treatment; No shape outline: genes modulated by either T or 1,25(OH)2D3;
dashed outline with white text: 1,25(OH)2D3 or T modulation is enhanced by the presence of T or 1,25(OH)2D3 respectively (synergy); solid
outline with white text: additive effect of T and 1,25(OH)2D3 on mRNA levels; solid outline with black text: synergistic effect of T and 1,25(OH)2D3
on mRNA levels. Genes reported to be ion binding or ion channels are indicated (Ca
2+: yellow, Cl
-; blue, K
+: purple, Na
+: blue, Zn
2+: blue).
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Page 4 of 15and, as revealed by comparing Figure 2C and additional
files 1 and 2, the combination of the two hormones also
additively or synergistically modulates a significantly
greater number of genes than either hormone alone. It
is evident that T and 1,25(OH)2D3 individually modulate
t h ee x p r e s s i o no fm a n yo ft h eg e n e si nt h e s eo n t o l o g i e s
while the combination of the two hormones modulates
a significant number of additional genes.
qPCR Validation of Microarray Analyses
Validation of the microarray data of selected genes asso-
ciated with the gene sets was performed in LNCaP cells
after treatment with T and 1,25(OH)2D3 over a 72 h
time course. The effects of these treatments on the
expression of AR and VDR, as well as two well charac-
terized androgen responsive genes, prostate specific anti-
gen (PSA) and TMPRSS2, and CYP24A1, the classical
VDR target gene are shown in Figure 3. Neither the AR
nor VDR transcripts are significantly induced in LNCaP
cells by T. However, 1,25(OH)2D3 alone or in combina-
tion with T increases the steady state level of AR
mRNA at 48 and 72 h. This corresponds to a consistent
increase in the level of the androgen receptor in the
nucleus after treatment with 1,25(OH)2D3 in the
absence or presence of T (additional file 3). Both hor-
mones increase the transcript levels of PSA and
Table 1 Gene Set Enrichment Analysis of representative gene sets identified as significantly enriched after 1,25(OH)
2D3 treatment in the presence of androgen in LNCaP cells.
Biological Process Testosterone 1,25(OH)2D3 T&D
Median
Change
p-value Median
Change
p-value Median
Change
p-value
Mitosis -1.54 3.51E-10 -1.98 3.63E-07 -3.63 1.27E-15
Microtubule-based movement -1.62 2.54E-05 -2.11 1.17E-04 -4.19 5.78E-07
Chromosome segregation -1.61 1.11E-03 -1.99 2.13E-03 -3.44 1.12E-04
Anaphase-promoting complex-dependent proteasomal ubiquitin-
dependent protein catabolic process
-1.47 5.90E-03 n/a n/a -3.63 2.10E-03
DNA repair n/a n/a -1.77 1.08E-02 -2.55 2.24E-03
DNA recombination n/a n/a -2.02 4.30E-02 -3.42 1.41E-02
Phosphoinositide-mediated signaling n/a n/a -1.73 4.97E-02 -2.40 1.60E-02
Elevation of cytosolic calcium ion concentration n/a n/a 2.02 1.76E-02 3.43 2.95E-02
(False Discovery Rate <5%)
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Figure 3 Validation of changes in the mRNA levels of AR, VDR, PSA, TMPRSS2 and CYP24A1. LNCaP cells were treated with 5 nM T and
100 nM 1,25(OH)2D3 alone and in combination and transcript levels were measured by Real Time-PCR over a 72 h time course. Fold changes
greater than 0.8 are statistically significant; values within the shaded areas in each graph are not significantly modulated (0.8 or below after
transformation). Comparisons between different treatment groups were analyzed using one-way ANOVA; differences were considered significant
if p < 0.05 (*), NS: not significant. Significant changes (p < 0.05) in at least two out of three time points were required for the changes to be
considered biologically relevant. Note: Scales on the ordinate axis vary from transcript to transcript.
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Page 5 of 15TMPRSS2, and the effect of the two hormones together
is additive. The classic VDR target gene CYP24A1 is
strongly induced by 1,25(OH)2D3, however T alone has
little or no effect on its expression. These data demon-
strate that the two intracellular signaling pathways are
active in LNCaP cells and that the VDR-mediated sig-
naling significantly affects the response of both andro-
gen responsive PSA and TMPRSS2 genes.
Representative qPCR validation data, grouped by GO
classification, are shown in Figure 4 (cell cycle) and Fig-
ure 5 (ion homeostasis), and the changes in the expres-
sion of genes associated with other ontologies are
shown in additional file 4 (cell survival and cell death),
and additional file 5 (lipid metabolism, angiogenesis,
DNA repair). It is clear from these data that a number
of genes are modulated by the combination of the two
steroids either additively (CYP2U1, HPGD, CXCR4,
CACNG4, KCNMB4, GMNN) or synergistically
(CCNA2, CDC20, CCNB2, Survivin/BIRC5, GADD45G,
E 2 F 1 ,I T P R 1 ,B R C A 1 ) .G e n e st h a ta r ek n o w nt o
modulate the cell cycle (CCNA2, CDC20, CCNB2) are
down regulated by T and 1,25(OH)2D3 in a similar man-
ner, reaching a nadir at 48 h after treatment (Figure 4).
T and 1,25(OH)2D3 also display prolonged effects on
the steady state levels of the transcripts when adminis-
tered together and the transcript levels of the genes
involved in prostaglandin and lipid metabolism
(CYP2U1 and HPGD), and calcium homeostasis
(TRPV6, ITPR1, and KCNMB4) show time-dependent
increases throughout the 72 h time course (Figure 5).
It is well established that ligand-activated AR and VDR
bind to cognate response elements (ARE and VDRE
respectively) to modulate gene transcription and thus
the coordination between T and 1,25(OH)2D3 may be
the consequence of receptor mediated transcription by
both AR and VDR. While in silico searches for ARE and
VDREs within 10 kb upstream or downstream of the
structural genes shown to be modulated by T or 1,25
(OH)2D3 or both, demonstrate that many of the genes
have canonical response elements in their promoters
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Figure 4 Validation of changes in the mRNA levels of cell cycle regulators. CCNA2, GMNN, CDC20 and CCNB2 transcript levels were
measured over a 72 h time course in LNCaP cells after treatment with 5 nM T and 100 nM 1,25(OH)2D3 alone and in combination. Other details
as shown in Figure 3.
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Page 6 of 15(additional file 6), nearly 50% of the genes identified in
the expression microarray analysis appear to lack func-
tional hormone response elements (either ARE or VDRE
or both) in their promoters (additional file 6). For
instance, genes that have previously been documented
to be only 1,25(OH)2D3 inducible and/or contain VDRE
at their promoters (KCNMB4, CXCR4) are also modu-
lated by T (Figures 5 and additional file 4). Furthermore,
genes such as CDC20 that lack both VDREs and AREs
are down regulated by 1,25(OH)2D3 and T together
while neither steroid alone has significant effects on
gene expression (Figures 4 and additional file 5). These
data demonstrate that 1,25(OH)2D3 has distinct effects
on the regulation of transcript levels and that for a sig-
nificant proportion the genes, the effects of 1,25(OH)
2D3 require the presence of T for maximal effect.
Furthermore, it appears that in addition to modulating
transcription of the responsive genes, T and 1,25(OH)
2D3 modulate the stability of the transcripts via modula-
tion of miRNA expression.
Effect of T and 1,25(OH)2D3 on miRNA expression
To examine the effect of T and 1,25(OH)2D3 on miRNA
expression, total RNA prepared from LNCaP cells 48 h
after treatment using the same experimental paradigm
outlined above was analyzed on the Agilent Human
miRNA microarray v3, which contains 866 human miR-
NAs from the Sanger database v12.0. The miRNA
expression profiles in LNCaP cells after treatment clus-
ter to the different treatment groups are shown in Fig-
ure 6A. Statistical analysis with a stringent cut-off of 2.0
fold, identifies 15 miRNAs that are significantly modu-
l a t e db yTa n d1 , 2 5 ( O H ) 2D3 (Table 2). The majority of
miRNAs identified are up regulated by T and 1,25(OH)
2D3 additively, including miR-29ab and miR-371/373
clusters. In contrast, two miRNAs, including miR-17
and miR-20a, members of the miR-17/92 cluster, are
down regulated by T and 1,25(OH)2D3 synergistically.
Bioinformatic analysis using the available miRNA target
prediction databases (TargetScan Human v5.1) identifies
approximately 8500 putative mRNA targets of these
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Figure 6 The effect of T and 1,25(OH)2D3 on miRNA expression in LNCaP cells. Cells were plated as described in Material and Methods,
and treated with 5 nM T and 100 nM 1,25(OH)2D3 alone or in combination for 48 h. Total RNA was extracted and interrogated on Agilent
Human miRNA v3 arrays. Three independent replicates were used for the analysis. Panel A: hierarchical clustering of the miRNA array data using
the GeneSpring GX10 software. Panel B: Gene Ontology analysis of mRNA targets of miRNAs, predominantly focused on those that are targeted
at the 3’UTR and affect the transcript stability. The inverse correlations of miRNAs targeted mRNAs and their associated Gene Ontology grouping
are summarized and color coded. Magenta: gene up regulated by treatment; Green: down regulated by treatment; No shape outline: genes
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Table 2 miRNAs differentially modulated by 1,25(OH)2D3 and T alone or in combination in LNCaP cells, identified by
Agilent Human miRNA microarray v3.
miRNA Seed Testosterone 1,25(OH)2D3 T + 1,25(OH)2D3
hsa-miR-17 aaagug -1.237 -1.255 -2.337
hsa-miR-20a aaagug -1.220 -1.287 -2.318
hsa-miR-20b aaagug -1.174 -1.391 -2.273
hsa-miR-542-5p cgggga -1.232 2.304 1.197
hsa-miR-29b agcacc 1.317 1.911 2.081
hsa-miR-1207-5p ggcagg 1.756 1.637 2.242
hsa-miR-22 agcugc 1.691 1.745 2.312
hsa-miR-1915 cccagg 2.005 2.044 3.007
hsa-miR-29a agcacc 2.122 2.577 3.108
hsa-miR-371-5p cucaaa 1.918 2.163 3.197
has-miR-663 ggcggg 2.293 2.561 3.685
hsa-miR-134 gugacu 2.995 2.923 4.597
hsa-miR-135a* auaggg 2.609 2.773 4.818
hsa-miR-1181 cgucgc 3.003 3.454 5.775
hsa-miR-629* uucucc 3.143 3.263 6.160
The seed sequence corresponds to individual miRNAs is indicated.
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Page 8 of 15miRNAs. However, most of these targets are not
expressed in the prostate and are not identified as differ-
entially regulated by T and 1,25(OH)2D3 by microarray.
In total, 264 target transcripts are responsive to T and
1,25(OH)2D3 in LNCaP cells and show an inverse asso-
ciation with the targeting miRNA(s) (Figure 6B). This
corresponds to approximately 23% of the genes modu-
l a t e db yTa n d1 , 2 5 ( O H ) 2D3 in LNCaP cells. However
this is at best a rough estimate since many of the targets
of the modulated miRNAs identified by Target Scan
have not yet been validated in LNCaP cells. A complete
list of the miRNAs and their mRNA targets is provided
in additional file 7.
The effects of T and 1,25(OH)2D3 on the steady state
levels of selected miRNAs were further assessed in
LNCaP cells by TaqMan
® qPCR to validate microarray
data. T and 1,25(OH)2D3 alone showed time-dependent
induction of miR-29a, miR-29b, miR-21, miR-22 and
miR-134 expression in LNCaP cells while the combina-
tion of the two have a more rapid additive effects on
these miRNAs (Figure 7). In contrast, neither steroid
alone down regulates miR-17 and miR-20a of the miR-
17/92 cluster, however the combination of T and 1,25
(OH)2D3 significantly down regulates miR-17 and miR-
20a, demonstrating the synergistic ability of T and 1,25
(OH)2D3 to modulate miRNA levels (Figure 8). We have
also assessed the changes of miR-18a, another member
of the miR-17/92 cluster. Changes in miR-18a transcript
levels showed a similar pattern as that of miR-17 and
20a, suggesting that T and 1,25(OH)2D3 together
modulate all members of the miR-17/92 cluster rather
than selectively down regulating individual members of
the cluster.
In addition to the miRNAs identified from the micro-
array analysis, we have also assessed the effect of T and
1,25(OH)2D3 on miRNAs that have been reported to be
deregulated in prostate cancer. The oncogenic miR-221,
which has been reported to contribute to androgen-
resistance phenotype is slightly down regulated by T
and 1,25(OH)2D3 at 48 h, though the fold change is not
statistically significant (additional file 8). Changes in the
AR-inducible [35] and VDR-inducible [43] miR-125b are
also not significant in LNCaP cells in this experimental
paradigm (additional file 8). However, as already shown,
the steady state levels of miR-21 are up regulated by T
and 1,25(OH)2D3 in LNCaP cells with the highest fold-
induction at 72 h in the presence of both hormones
(Figure 7). This implies that the expression of miR-21
targets, such as PDCD4, may also be modulated by AR
and VDR in LNCaP cells.
Discussion
The data presented here demonstrate that both T and
1,25(OH)2D3 modulate the mRNA and miRNA profiles
in LNCaP cells, and that the combination of the two
hormones modulates a significantly larger cohort of
transcripts than either hormone alone. In most cases,
the effects of the two hormones are additive or synergis-
tic. Since the predicted changes in the cohort of proteins
present in the cells would be expected to influence the
-10
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Page 9 of 15response to therapeutic agents, this raises questions
regarding the interpretation of previous in vitro data
describing the responsiveness of prostate cancer cell
lines grown in the absence of these hormones.
T h et i m ef r a m ew eh a v ec h o s en for the initial micro-
array experiments (48 h) and the times chosen for qPCR
validation (24, 48 and 72 h) were selected based on pre-
vious experiments examining the induction of apoptosis
in LNCaP cells by diverse agents including bicalutamide
and Iejimalide [44]. These time points will not discrimi-
nate between primary effects of T and 1,25(OH)2D3 on
transcription and secondary effects which may be due to
either the modulation of miRNA, and subsequent degra-
dation of target mRNAs or cascading regulation of tran-
scription of other genes. However, this time frame is
appropriate to examine the effects of induced miRNAs
on transcript stability.
Bioinformatic analysis demonstrates that T and 1,25
(OH)2D3 alter the expression of genes associated with
several relevant gene ontologies that clearly have the
potential to significantly influence the biology of the
tumor cells, their interaction with the tumor microen-
vironment and their response to therapeutic interven-
tion. Perhaps the most important of these changes relate
to the regulation of calcium ion homeostasis and cell
cycle progression. One of the primary physiological
roles of 1,25(OH)2D3 is to regulate calcium and phos-
phorus metabolism in bone. However, 1,25(OH)2D3 also
plays an important role in cell cycle regulation in many
cancers, including breast, ovarian and colon cancer,
through its interaction with the VDR [6,45-48]. In
LNCaP cells, 1,25(OH)2D3 induces the expression of
both voltage-gated (CACNG4) and non-voltage-gated
(TRPV6) Ca
2+ channels located on the plasma mem-
brane. Though TRPV6 is primarily modulated by VDR,
the full induction of ITPR1, annexin AII (ANXA2) and
S100A10, major components of the TRPV6 auxiliary
protein complex, requires the presence of both hor-
mones, as does the induction of the highly Ca
2+
sensitive PLC-δ3 (PLCD3). There is also a concurrent
increase in ITPR1 in response to T and 1,25(OH)2D3
which has been shown to lead to increased signaling
through the PI3K/AKT pathway [49]. This suggests that
in response to T and 1,25(OH)2D3, the production of
IP3 will increase, triggering the release of Ca
2+ from
endoplasmic reticulum (ER) stores via ITPR1, leading to
the activation of TRPV6 through S100A10, resulting in
an influx of Ca
2+ and augmenting intracellular Ca
2+
levels. In addition, diacylglycerol, produced by PLC
mediated cleavage of PIP2, may activate PKC, to further
increase the activity of TRPV6 via phosphorylation [50].
Together, these data suggest that the combination of T
and 1,25(OH)2D3 elevates the intracellular Ca
2+ level to
establish a new homeostatic set point without inducing
cell death. Since the induction of the execution phase of
apoptosis in prostate cancer cells requires the elevation
of intracellular free Ca
2+ into the micromolar range
[51], resetting the intracellular Ca
2+ concentration closer
to this threshold may render tumor cells more sensitive
to apoptosis-inducing agents including doxorubicin,
bicalutamide and radiation. It is well known that uncon-
trolled release of Ca
2+ stores from the ER, for example
in response to thapsigargin, initiates apoptosis via the
activation of Ca
2+-dependent caspases accompanied by
release of cytochrome c through the mitochondrial per-
meability transition pore [52]. It is therefore likely that a
fine-tuned Ca
2+ balance within the cellular compart-
ments in prostate cancer cells occurs after treatment
with 1,25(OH)2D3 a n dt h u sp r e v e n t sC a
2+ overload in
the mitochondria and maintains other Ca
2+-dependent
signaling, which may include the modulation of miRNA
expression [53]. Importantly, both T and 1,25(OH)2D3
appear to be required to establish the elevated homeo-
static calcium levels. In this regard, the capacitative Ca
2+
entry that has been shown to block the development of
the apoptosis resistance phenotype such as that seen in
Bcl-2 over-expressing LNCaP cells [54,55] may be
equivalent to the elevated homeostatic Ca
2+ level
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Page 10 of 15i n d u c e db yTa n d1 , 2 5 ( O H ) 2D3,s u g g e s t i n gt h a ta d e -
quate levels of the two hormones should also prevent
the development of the apoptosis-resistant, or castration
resistant, phenotype in prostate cancer.
Many of the changes in the steady state mRNA levels
can be attributed to changes in transcriptional activity
due to the presence of functional AREs and/or VDREs
in the promoters of target genes. However, in silico
searches suggests that the promoters of nearly 40% of
the affected genes do not contain either response ele-
ment. Both T and 1,25(OH)2D3 have been shown to
induce rapid Ca
2+ influx via store-operated Ca
2+ (SOC)
channels whose activities are mediated by membrane
receptors (mVDR & mAR) and are related to the non-
genomic action of AR and VDR [56-58]. In addition, the
ligand-activated VDR can modulate transcription of
some target genes through Sp-1 sites [59-61]. Therefore,
it is likely that additional mechanisms are responsible
for the extensive modulation seen in response to the
two hormones.
As demonstrated here, T and 1,25(OH)2D3 coopera-
tively modulate a circumscribed group of miRNAs,
which mediate mRNA degradation depending on the
complementarity of the miRNA seed sequence to
sequences within the 3’UTR of the transcript. While
alterations in individual miRNAs are not as profound as
those seen in the mRNA profiles, many of the miRNAs
share identical seed sequences, which results in a cumu-
lative effect on the target transcripts. In LNCaP cells,
most of the miRNAs identified in this study are up
regulated in response to T and 1,25(OH)2D3,i n c l u d i n g
miR-21, miR-22, miR-29ab, miR-134 and miR-371-5p
and miR-1207-5p. Both miR-21 and miR-29b have pre-
viously been shown to be induced by R1881 in LNCaP
and LAPC-4 prostate cancer cells [62]. Induction of
these miRNAs results in substantial down regulation of
several large cohorts of genes classified by GO. Thus, in
addition to down regulating transcription through their
cognate hormone response elements, T and 1,25(OH)
2D3 can profoundly affect the stability of the transcripts
encoding proteins that function in cell cycle control,
cytoskeleton organization, and DNA damage repair
among others. In this context, MYCBP, a positive regu-
lator of c-Myc activity and a validated miR-22 target
should be repressed by T and 1,25(OH)2D3, thus inhibit-
ing c-Myc mediated transcription of E-box containing
genes [63]. In breast cancer cells, this correlates with
suppressed cell proliferation and anchorage-independent
growth suggesting that increased expression of miR-22
at 48 h in prostate tumor cells by T and 1,25(OH)2D3
may be partially responsible for cell cycle arrest and the
prevention of tumor progression. In LNCaP cells miR-
134 is very significantly up regulated by 1,25(OH)2D3 in
the absence and presence of T. The role of miR-134 in
prostate cancer has not been previously described, how-
ever the steady state level of miR-134 is modulated by
members of the p53/p73/p63 family as part of a
miRNA-tumor suppressor network [64]. Thus, increased
expression of miR-134 may further contribute to the
activity of T and 1,25(OH)2D3 to suppress tumor
growth.
While miR-21 was not identified in the microarray as
a T and/or 1,25(OH)2D3 r e g u l a t e dm i R N A ,i tw a si d e n -
tified in the more informative qPCR analysis as a target
of T and 1,25(OH)2D3, and the increases in the steady
state level of miR-21 are significant after 48 h of treat-
ment. Previous studies in breast and pancreatic cancer
cell lines have suggested that over expression of miR-21
may lead to increased cell proliferation and decreased
apoptosis through the targeted degradation of tumor
suppressor protein PDCD4 [62,65]. In prostate cancer
cells, these effects would be anticipated to counteract
the anti-proliferative effects of 1,25(OH)2D3,s u g g e s t i n g
that not all interactions between AR- and VDR-
mediated signaling are beneficial. Interestingly, neither
of the other miRNAs that have been implicated in pros-
tate tumor progression (miR-221 or miR-125b) is modu-
lated by T nor 1,25(OH)2D3 in this in vitro model
system. In addition to up regulating miRNAs that
encode cell cycle regulatory proteins and calcium ion
homeostasis, T and 1,25(OH)2D3 down regulate the
expression of the oncomiR cluster, miR-17/92. These
data suggest that miRNAs may play important roles in
T- and 1,25(OH)2D3-induced cell cycle arrest in prostate
cancer cells. The concurrent analysis of mRNA and
miRNA expression has demonstrated that many of the
combined effects of T and 1,25(OH)2D3 are modulated
by a small cohort of 15 miRNAs that are additively or
synergistically regulated by the two hormones. Since the
majority of men diagnosed with prostate cancer are
likely to be vitamin D insufficient [66], these data may
have a profound impact on our understanding of the
molecular mechanisms underlying the chemopreventive
and chemotherapeutic effects of vitamin D3. Based on
the data presented here, vitamin D deficiency is likely to
render tumor cells more aggressive and less sensitive to
chemotherapy. Given the trend toward “active surveil-
lance” for men diagnosed with early stage prostate can-
cer, understanding the cross talk between the androgen-
and vitamin D-mediated cellular effects may have a sig-
nificant impact on the care of men in the period
between diagnosis and the initiation of treatment. If
these two signaling pathways interact in tumor tissue as
demonstrated here, individual variations in dietary vita-
min D and/or sun exposure, as well as differences in cir-
culating T levels, may greatly influence the rate of
prostate tumor growth and the sensitivity of prostate
cancer to hormone and other chemotherapies. In this
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Page 11 of 15context, the age related decline in serum testosterone
may also contribute to the progression of prostate can-
cer. Thus, maintaining serum testosterone and com-
bined with supplementation of vitamin D may
substantially slow disease progression for men diagnosed
with very early stage cancer, extending the time between
diagnosis and treatment.
Methods
Cell Culture
LNCaP human prostate cancer cells, obtained from
American Type Culture Collection (Rockville, MD),
were grown in RPMI-1640 medium (Invitrogen, Carls-
bad, CA) supplemented with 10% FBS (Sigma-Aldrich,
St Louis, MO), 100 U/mL penicillin and 100 μg/mL
streptomycin. Cells were maintained at 37°C in a humi-
dified atmosphere of 95% air/5% CO2. For all the experi-
ments performed in this study, with the exception of
crystal violet assays, LNCaP cells were plated at a den-
s i t yo f1×1 0
6 cells per 150 cm
2 d i s hf o r4 8hp r i o rt o
treatment with 5 nM T (Sigma-Aldrich) and 100 nM
1,25(OH)2D3 (Sigma-Aldrich) alone or in combination.
The steroids were dissolved in ethanol, and control cells
were treated with the same volume of vehicle.
Crystal Violet Assay
LNCaP cells were seeded at 20,000 cells/well in 24 well
plates for 24 h prior to treatment with 5 nM T and 100
nM 1,25(OH)2D3 alone or in combination. Cells were
fixed with 2% glutaraldehyde in PBS for 20 min at room
temperature followed by staining with 0.1% crystal violet
(Sigma-Aldrich) for 30 min. The crystal violet stain was
s o l u b i l i z e di n0 . 2 %T r i t o nX - 1 0 0i nd d H 2Of o r3 0m i n
and the absorbance was read with Victor
3V 1420 Multi-
label Counter (PerkinElmer Inc, Waltham MA) at 590
nm. Three independent biological replicates were ana-
lyzed in triplicate.
Flow Cytometry
LNCaP cells were treated with 5 nM T and 100 nM 1,25
(OH)2D3 as described above. Cells treated with either
vehicle (EtOH) or 100 μM bicalutamide serve as the
negative and positive control, respectively. For cell cycle
analysis, the cells were treated for 24, 48 and 72 h and
harvested by trypsinization, followed by 90% ethanol
permeabilization overnight at -20°C. Permeabilized cells
were stained with 5 μg/mL propidium iodide (Sigma-
A l d r i c h )i nt h ep r e s e n c eo f0 . 0 1 5U / m LR N a s e( R o c h e
Applied Science, Indianapolis, IN) in PBS for 20 min at
room temperature. Samples were analyzed within 3 h of
labeling on BD™ LSR II Flow Cytometer (BD Bios-
ciences, San Jose, CA). A minimum of 10,000 events
were analyzed for each experimental condition. Three
independent biological replicates for each treatment
group were analyzed.
Apoptosis was analyzed using Apo-BrdU staining.
Cells were harvested by trypsinization and fixed with 4%
formaldehyde in PBS for 30 min on ice, followed by
70% ethanol permeabilization overnight at -20°C. Sam-
ples were enzymatically labeled with bromodeoxyuridine
triphosphate in TdT reaction buffer (Br-dUTP, 2.5 mM
cobalt chloride, and terminal transferase 24,000 U) for 1
h at 37°C to label the 3’-OH ends of fragmented DNA
(Roche). DNA strand breaks were counterlabeled with
FITC-conjugated anti-BrdU monoclonal antibody
according to the manufacturer’s directions (Phoenix
Flow Systems, San Diego, CA). Cells were counter-
stained with 5 μg/mL propidium iodide for 30 min at
room temperature. Samples were analyzed on BD™ LSR
II Flow Cytometer (BD Biosciences) within 3 h of label-
ing and a minimum of 10,000 events were analyzed for
each experimental condition. Three independent biologi-
cal replicates for each treatment group were analyzed.
mRNA Microarray Analysis
Total RNA isolated from LNCaP cells was processed
using standard protocols for Nimblegen arrays. Briefly
10 μg of total RNA was reverse transcribed to cDNA
using oligo-dT primers and Superscript II (Invitrogen),
converted to double stranded cDNA and Klenow labeled
with Cy3-labeled random 9-mers before hybridization to
Nimblegen-Human-HG18 4 × 72 microarrays at 42°C
for 16 h using a Nimblegen Hybridization system. The
arrays were washed and scanned on a Genepix 4000B
scanner following which the data was extracted using
NimbleScan software. Further data analysis was per-
formed using GeneSpring GX10. The raw dataset is
available as a curated dataset at GEO (SuperSeries
GSE23815, SubSeries GSE17461). Three independent
biological replicates for each treatment group were
analyzed.
miRNA Microarray Analysis
Total RNA was processed and hybridized to Agilent
Human miRNA microarrays using standard protocols.
100 ng of total RNA was dephosphorylated with calf
intestinal phosphatase and end-labeled with Cy3-pCp by
T4 RNA ligase prior to an overnight hybridization at 55°
C onto Agilent Human miRNA v3 (Sanger release 12.0)
microarrays. The arrays were washed and scanned on a
high resolution GC2565CA Agilent Scanner using the
manufacturer’s recommended settings. The raw data
was extracted using Agilent Feature Extraction software
v10.1.1 and imported into GeneSpring GX10 for further
analysis. The raw data is available as a curated dataset at
GEO (SuperSeries GSE23815, SubSeries GSE23814).
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Page 12 of 15qPCR Validation of Microarray Data
Changes in mRNA and miRNA identified by microarray
were validated in independent biological replicates.
LNCaP cells were plated and treated as previously
described for 24, 48 and 72 h. Cells were harvested by
trypsinization and total RNA (both mRNA and miRNA)
was extracted using miRNeasy mini kit (Qiagen, Valen-
cia, CA). Reverse transcription PCR reactions were per-
formed with 1.5 μg total RNA using Taqman
® Reverse
Transcription Reagents (Applied Biosystems, Carlsbad,
CA) to synthesize cDNA for mRNA expression analysis.
The reaction mixture was incubated for 10 min at 25°C,
1 h at 37°C and 5 min at 95°C and kept at -20°C until
further analysis. qPCR probes for each gene were
designed using Primer-Blast (National Center for Bio-
technology Information) with default settings and
synthesized by Integrated DNA Technologies (Coralville,
IA). The list of primers for each gene is available in
additional file 9. SYBR Green reactions with SYBR
®
Green PCR Master Mix (Applied Biosystems) were ana-
lyzed using the ABI 7900HT Fast Real-Time PCR Sys-
tem (Applied Biosystems): 50°C for 2 min, 95°C for 10
min, 95°C for 15 sec and 60°C for 1 min, repeated for
40 cycles. Relative expression levels of each gene in real
time were analyzed using the 2
-ΔΔC
T method [67] and
presented as ratio relative to the expression of the
housekeeping gene GAPDH. For miRNA expression
analysis, 10 ng total RNA were used to make cDNA
with TaqMan
® MicroRNA Reverse Transcription
Reagents (Applied Biosystems). The reaction mixture
was incubated for 30 min at 16°C, 30 min at 42°C and 5
min at 85°C and kept at -20°C until further analysis.
TaqMan
® MicroRNA Assays were used to evaluate
miRNA expression according to manufacturer’sp r o t o -
col. TaqMan reactions were analyzed using the ABI
7900HT Fast Real-Time PCR System: 95°C for 10 min,
95°C for 15 sec and 60°C for 60 sec repeated for 40
cycles. Relative expression levels of each miRNA in real
time were analyzed using the 2
-ΔΔCTm e t h o dw i t hU 6
snRNA as the reference control. Each sample was repli-
cated twice from three independent sets of RNA pre-
parations. Results are tabulated as mean ± SD and
presented as fold change after transformation to show
divergence from no effect (zero fold change).
Statistical Analysis of Microarray Data
For mRNA microarray analysis in GeneSpring GX10,
the gene list was filtered to exclude entities which
showed low signal values across all samples (i.e bottom
20
th percentile). Statistically significant genes from each
expression profile were selected using one-way ANOVA
(p ≤ 0.05). The multiple testing correction Benjamini
and Hochberg false discovery rate (FDR) (p-value <0.05)
was integrated within each test. A fold change cut-off at
1.5 fold was implemented to generate the final list of
differentially expressed genes. Genes passing the statisti-
cal tests were further assigned into their gene ontology
(GO) grouping using DAVID Bioinformatics Resources
v6.7 (NIAID) with the default setting, essentially as pre-
viously described [68]. Significantly regulated and
enriched GO groups were selected for qPCR analysis.
For miRNA microarray analysis, the raw data was
imported into GeneSpring GX10, log2 transformed, nor-
malized to the 75
th percentile following which the entity
list was filtered to exclude probes that showed low sig-
nal values across all treatment groups (i.e. bottom 20
th
percentile). This list was further filtered to only include
entities that were marked “present;’ or “marginal” in all
3 replicates for at least one of the 4 treatment groups.
Entities with fold changes greater than 2.0 were consid-
ered significant when p < 0.05 using one-way ANOVA
with Benjamini-Hochberg FDR post-test. Targets of
miRNAs that passed the statistical test were identified
using TargetScan Human v5.1 from Whitehead Institute
for Biomedical Research. Gene targets whose mRNA
expression levels were inversely proportional to the cor-
responding miRNA expression levels were considered
concordant and were further analyzed for their enrich-
ment in Gene Ontology grouping.
Additional material
Additional file 1: Analysis of Selected Gene Ontologies Modulated
by T in LNCaP Cells. Functional annotation of each gene was assigned
based on DAVID Bioinformatics Resources 2008 (NIAID). Magenta: gene
up regulated by treatment; Green: down regulated by treatment; No
shape outline: genes modulated by either T or 1,25(OH)2D3; dashed
outline with white text: 1,25(OH)2D3 or T modulation is enhanced by the
presence of T or 1,25(OH)2D3 respectively (synergy); solid outline with
white text: additive effect of T and 1,25(OH)2D3 on mRNA levels; solid
outline with black text: synergistic effect of T and 1,25(OH)2D3 on mRNA
levels. Genes reported to be ion binding or ion channels are indicated
(Ca
2+: yellow, Zn
2+: blue)
Additional file 2: Analysis of Selected Gene Ontologies Modulated
by 1,25(OH)2D3 in LNCaP Cells. Functional annotation of each gene
was assigned based on DAVID Bioinformatics Resources 2008 (NIAID).
Magenta: gene up regulated by treatment; Green: down regulated by
treatment; No shape outline: genes modulated by either T or 1,25(OH)
2D3; dashed outline with white text: 1,25(OH)2D3 or T modulation is
enhanced by the presence of T or 1,25(OH)2D3 respectively (synergy);
solid outline with white text: additive effect of T and 1,25(OH)2D3 on
mRNA levels; solid outline with black text: synergistic effect of T and 1,25
(OH)2D3 on mRNA levels. Genes reported to be ion binding or ion
channels are indicated (Ca
2+: yellow, Zn
2+: blue)
Additional file 3: Immunoblotting analysis of 5 nM T and 100 nM
1,25(OH)2D3 on nuclear AR and VDR expression. LNCaP cells were
treated with 5 nM T and 100 nM 1,25(OH)2D3 alone and in combination
for 48 h. Nuclear proteins were extracted and ran on 10% SDS-PAGE and
transferred to PVDF membrane. Antibodies against AR (Millipore) and
VDR (Santa Cruz) were used to detect the protein levels of AR and VDR
in the nucleus. Lamin A/C was used as the loading control.
Additional file 4: Validation on changes in the mRNA levels of
genes involved in cell death. GADD45G, STK17B, E2F1 and Survivin/
BIRC5 transcript levels were measured over a 72 h time course in LNCaP
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Page 13 of 15cells after treatment with 5 nM T and 100 nM 1,25(OH)2D3 alone and in
combination. Other details as shown in Figure 3.
Additional file 5: Validation on changes in the mRNA levels of
selected genes involved in lipid metabolism, angiogenesis, calcium
induced signaling and DNA repair. CYP2U1, HPGD, CXCR4, ANXA2,
EGFR and BRCA1 transcripts were measured over a 72 h time course in
LNCaP cells after treatment with 5 nM T and 100 nM 1,25(OH)2D3. Fold
changes greater than 0.8 are statistically significant; values within the
shaded areas in each graph are not significantly modulated (0.8 or below
after transformation). Comparisons between different treatment groups
were analyzed using one-way ANOVA; differences were considered
significant if p < 0.05 (*), NS: not significant. Significant changes (p <
0.05) in at least two out of three time points were required for the
changes to be considered biologically relevant. Note: Scales on the
ordinate axis vary from transcript to transcript.
Additional file 6: Differentially regulated mRNAs by T and 1,25(OH)
2D3 in LNCaP cells after 48 h of treatment. Down regulated mRNAs
are shaded in green and up regulated mRNAs are shaded in red. The
presence (1) or absence (0) of hormone response elements are indicated
based on the in silico searches for androgen response elements (AREs)
and/or vitamin D response elements (VDREs) in the promoters of T and
1,25(OH)2D3 responsive genes identified from microarray analysis.
Additional file 7: miRNA targeted that are differentially regulated
by T and 1,25(OH)2D3 in LNCaP cells after 48 h of treatment. Down
regulated mRNAs/miRNAs are shaded in green and up regulated
mRNAs/miRNAs are shaded in red.
Additional file 8: Effects of T and 1,25(OH)2D3 on the expression of
miR-125b and miR-221 in LNCaP cells. LNCaP cells were treated with
5 nM T and 100 nM 1,25(OH)2D3 alone and in combination and
transcript levels were measured by TaqMan
®® qPCR over a 72 h time
course. Other details as shown in Figure S4.
Additional file 9: Sequence of Primers used for qPCR.
Acknowledgements
The research presented in this manuscript was supported by an operating
grant from the USPHS (RO1 CA101114-04). The authors would like to thank
David Frank and Marcy Kuentzel for excellent technical help with the
microarray experiments; and Dr. Andrew Reilly for his help and insights into
the analysis of the microarray data.
Author details
1Department of Biomedical Sciences, University at Albany, State University of
New York, Albany, NY 12222, USA.
2Cancer Research Center, University at
Albany, Rensselaer, NY 12144, USA.
3Department of Environmental Health
Sciences, University at Albany, State University of New York, Albany, NY
12222, USA.
Authors’ contributions
WWW was responsible for execution of the experiments described in this
manuscript and the analysis of the data. She also wrote the first draft of the
manuscript. NC assisted with the analysis of the microarray data and SVC
performed the microarray experiments and the initial bioinformatic analyses.
JW was responsible for experimental design and editing the manuscript. MT
was responsible for experimental design and editing the manuscript. All
authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 8 March 2011 Accepted: 18 May 2011 Published: 18 May 2011
References
1. Surveillance Epidemiology and End Results Web. [http://seer.cancer.gov].
2. Lamont KR, Tindall DJ: Androgen regulation of gene expression. Adv
Cancer Res 2010, 107:137-162.
3. Vis AN, Schroder FH: Key targets of hormonal treatment of prostate
cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU
Int 2009, 104:438-448.
4. Vis AN, Schroder FH: Key targets of hormonal treatment of prostate
cancer. Part 2: the androgen receptor and 5alpha-reductase. BJU Int
2009, 104:1191-1197.
5. Giovannucci E: Expanding roles of vitamin D. J Clin Endocrinol Metab 2009,
94:418-420.
6. Thorne J, Campbell MJ: The vitamin D receptor in cancer. Proc Nutr Soc
2008, 67:115-127.
7. Garland CF, Gorham ED, Mohr SB, Garland FC: Vitamin D for cancer
prevention: global perspective. Ann Epidemiol 2009, 19:468-483.
8. Schwartz GG, Skinner HG: Vitamin D status and cancer: new insights. Curr
Opin Clin Nutr Metab Care 2007, 10:6-11.
9. Tseng M, Breslow RA, DeVellis RF, Ziegler RG: Dietary patterns and
prostate cancer risk in the National Health and Nutrition Examination
Survey Epidemiological Follow-up Study cohort. Cancer Epidemiol
Biomarkers Prev 2004, 13:71-77.
10. Barnett CM, Nielson CM, Shannon J, Chan JM, Shikany JM, Bauer DC, et al:
Serum 25-OH vitamin D levels and risk of developing prostate cancer in
older men. Cancer Causes Control 2010, 21:1297-1303.
11. Park SY, Cooney RV, Wilkens LR, Murphy SP, Henderson BE, Kolonel LN:
Plasma 25-hydroxyvitamin D and prostate cancer risk: the multiethnic
cohort. Eur J Cancer 2010, 46:932-936.
12. Rhee HV, Coebergh JW, Vries ED: Sunlight, vitamin D and the prevention
of cancer: a systematic review of epidemiological studies. Eur J Cancer
Prev 2009.
13. Yin L, Raum E, Haug U, Arndt V, Brenner H: Meta-analysis of longitudinal
studies: Serum vitamin D and prostate cancer risk. Cancer Epidemiol 2009,
33:435-445.
14. Alagbala AA, Moser MT, Johnson CS, Trump DL, Foster BA: Characterization
of Vitamin D insensitive prostate cancer cells. J Steroid Biochem Mol Biol
2007, 103:712-716.
15. Banach-Petrosky W, Ouyang X, Gao H, Nader K, Ji Y, Suh N, et al: Vitamin D
inhibits the formation of prostatic intraepithelial neoplasia in Nkx3.1;
Pten mutant mice. Clin Cancer Res 2006, 12:5895-5901.
16. Mordan-McCombs S, Brown T, Wang WL, Gaupel AC, Welsh J,
Tenniswood M: Tumor progression in the LPB-Tag transgenic model of
prostate cancer is altered by vitamin D receptor and serum testosterone
status. J Steroid Biochem Mol Biol 2010, 121:368-371.
17. Murthy S, Agoulnik IU, Weigel NL: Androgen receptor signaling and
vitamin D receptor action in prostate cancer cells. Prostate 2005,
64:362-372.
18. Oades GM, Dredge K, Kirby RS, Colston KW: Vitamin D receptor-dependent
antitumour effects of 1,25-dihydroxyvitamin D3 and two synthetic
analogues in three in vivo models of prostate cancer. BJU Int 2002,
90:607-616.
19. Saito T, Okamoto R, Haritunians T, O’Kelly J, Uskokovic M, Maehr H, et al:
Novel Gemini vitamin D(3) analogs have potent antitumor activity. J
Steroid Biochem Mol Biol 2008, 112:151-156.
20. Washington MN, Kim JS, Weigel NL: 1alpha,25-dihydroxyvitamin D(3)
inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein
(Rb)-independent G(1) arrest. Prostate 2010.
21. Bao BY, Yao J, Lee YF: 1alpha, 25-dihydroxyvitamin D3 suppresses
interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis
2006, 27:1883-1893.
22. Ben Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ:
1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible
factor-1/vascular endothelial growth factor pathway in human cancer
cells. Mol Cancer Ther 2007, 6:1433-1439.
23. Jiang F, Bao J, Li P, Nicosia SV, Bai W: Induction of ovarian cancer cell
apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of
telomerase. J Biol Chem 2004, 279:53213-53221.
24. Kizildag S, Ates H, Kizildag S: Treatment of K562 cells with 1,25-
dihydroxyvitamin D(3) induces distinct alterations in the expression of
apoptosis-related genes BCL2, BAX, BCL(XL), and p21. Ann Hematol 2009.
25. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE: 1 alpha,25-
dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res
2000, 87:214-220.
26. Campbell MJ, Koeffler HP: Toward therapeutic intervention of cancer by
vitamin D compounds. J Natl Cancer Inst 1997, 89:182-185.
Wang et al. Molecular Cancer 2011, 10:58
http://www.molecular-cancer.com/content/10/1/58
Page 14 of 1527. Miller GJ, Stapleton GE, Hedlund TE, Moffat KA: Vitamin D receptor
expression, 24-hydroxylase activity, and inhibition of growth by
1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell
lines. Clin Cancer Res 1995, 1:997-1003.
28. Zhuang SH, Burnstein KL: Antiproliferative effect of 1alpha,25-
dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves
reduction of cyclin-dependent kinase 2 activity and persistent G1
accumulation. Endocrinology 1998, 139:1197-1207.
29. Weigel NL: Interactions between vitamin D and androgen receptor
signaling in prostate cancer cells. Nutr Rev 2007, 65:S116-S117.
30. Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al: Genomic
profiling of microRNA and messenger RNA reveals deregulated
microRNA expression in prostate cancer. Cancer Res 2008, 68:6162-6170.
31. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T:
MicroRNA expression profiling in prostate cancer. Cancer Res 2007,
67:6130-6135.
32. Li T, Li D, Sha J, Sun P, Huang Y: MicroRNA-21 directly targets MARCKS
and promotes apoptosis resistance and invasion in prostate cancer cells.
Biochem Biophys Res Commun 2009, 383:280-285.
33. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al:
miR-21: an androgen receptor-regulated microRNA that promotes
hormone-dependent and hormone-independent prostate cancer
growth. Cancer Res 2009, 69:7165-7169.
34. Sun T, Yang M, Kantoff P, Lee GS: Role of microRNA-221/-222 in cancer
development and progression. Cell Cycle 2009, 8:2315-2316.
35. Shi XB, Xue L, Yang J, Ma AH, Zhao J, Xu M, et al: An androgen-regulated
miRNA suppresses Bak1 expression and induces androgen-independent
growth of prostate cancer cells. Proc Natl Acad Sci USA 2007,
104:19983-19988.
36. Shi XB, Xue L, Ma AH, Tepper CG, Kung HJ, White RW: miR-125b promotes
growth of prostate cancer xenograft tumor through targeting pro-
apoptotic genes. Prostate 2011, 71:538-549.
37. Lin SL, Chiang A, Chang D, Ying SY: Loss of mir-146a function in
hormone-refractory prostate cancer. RNA 2008, 14:417-424.
38. Rokhlin OW, Scheinker VS, Taghiyev AF, Bumcrot D, Glover RA, Cohen MB:
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate
cancer. Cancer Biol Ther 2008, 7:1288-1296.
39. Thorne JL, Maguire O, Doig CL, Battaglia S, Fehr L, Sucheston LE, et al:
Epigenetic control of a VDR-governed feed-forward loop that regulates
p21(waf1/cip1) expression and function in non-malignant prostate cells.
Nucleic Acids Res 2011, 39:2045-2056.
40. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D:
Analysis of vitamin D-regulated gene expression in LNCaP human
prostate cancer cells using cDNA microarrays. Prostate 2004, 59:243-251.
41. Peehl DM, Shinghal R, Nonn L, Seto E, Krishnan AV, Brooks JD, et al:
Molecular activity of 1,25-dihydroxyvitamin D3 in primary cultures of
human prostatic epithelial cells revealed by cDNA microarray analysis. J
Steroid Biochem Mol Biol 2004, 92:131-141.
42. Wang TT, Tavera-Mendoza LE, Laperriere D, Libby E, MacLeod NB, Nagai Y,
et al: Large-scale in silico and microarray-based identification of direct
1,25-dihydroxyvitamin D3 target genes. Mol Endocrinol 2005,
19:2685-2695.
43. Mohri T, Nakajima M, Takagi S, Komagata S, Yokoi T: MicroRNA regulates
human vitamin D receptor. Int J Cancer 2009, 125:1328-1333.
44. Wang WL, McHenry P, Jeffrey R, Schweitzer D, Helquist P, Tenniswood M:
Effects of Iejimalide B, a marine macrolide, on growth and apoptosis in
prostate cancer cell lines. J Cell Biochem 2008, 105:998-1007.
45. Colston KW, Hansen CM: Mechanisms implicated in the growth
regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 2002,
9:45-59.
46. Harris DM, Go VL: Vitamin D and colon carcinogenesis. J Nutr 2004,
134:3463S-3471S.
47. Welsh J, Wietzke JA, Zinser GM, Smyczek S, Romu S, Tribble E, et al: Impact
of the Vitamin D3 receptor on growth-regulatory pathways in mammary
gland and breast cancer. J Steroid Biochem Mol Biol 2002, 83:85-92.
48. Zhang X, Nicosia SV, Bai W: Vitamin D receptor is a novel drug target for
ovarian cancer treatment. Curr Cancer Drug Targets 2006, 6:229-244.
49. Khan MT, Wagner L, Yule DI, Bhanumathy C, Joseph SK: Akt kinase
phosphorylation of inositol 1,4,5-trisphosphate receptors. J Biol Chem
2006, 281:3731-3737.
50. Al Ansary D, Bogeski I, Disteldorf BM, Becherer U, Niemeyer BA: ATP
modulates Ca2+ uptake by TRPV6 and is counteracted by isoform-
specific phosphorylation. FASEB J 2010, 24:425-435.
51. Tombal B, Denmeade SR, Gillis JM, Isaacs JT: A supramicromolar elevation
of intracellular free calcium ([Ca(2+)](i)) is consistently required to
induce the execution phase of apoptosis. Cell Death Differ 2002,
9:561-573.
52. Szabadkai G, Duchen MR: Mitochondria: the hub of cellular Ca2+
signaling. Physiology (Bethesda) 2008, 23:84-94.
53. Sonkoly E, Wei T, Pavez LE, Suzuki H, Kato M, Torma H, et al: Protein kinase
C-dependent upregulation of miR-203 induces the differentiation of
human keratinocytes. J Invest Dermatol 2010, 130:124-134.
54. Vanden Abeele F, Skryma R, Shuba Y, Van Coppenolle F, Slomianny C,
Roudbaraki M, et al: Bcl-2-dependent modulation of Ca(2+) homeostasis
and store-operated channels in prostate cancer cells. Cancer Cell 2002,
1:169-179.
55. Flourakis M, Prevarskaya N: Insights into Ca2+ homeostasis of advanced
prostate cancer cells. Biochim Biophys Acta 2009, 1793:1105-1109.
56. Foradori CD, Weiser MJ, Handa RJ: Non-genomic actions of androgens.
Front Neuroendocrinol 2008, 29:169-181.
57. Nakagawa K, Tsugawa N, Okamoto T, Kishi T, Ono T, Kubodera N, et al:
Rapid control of transmembrane calcium influx by 1alpha,25-
dihydroxyvitamin D3 and its analogues in rat osteoblast-like cells. Biol
Pharm Bull 1999, 22:1058-1063.
58. Steinsapir J, Socci R, Reinach P: Effects of androgen on intracellular
calcium of LNCaP cells. Biochem Biophys Res Commun 1991, 179:90-96.
59. Cheng HT, Chen JY, Huang YC, Chang HC, Hung WC: Functional role of
VDR in the activation of p27Kip1 by the VDR/Sp1 complex. J Cell
Biochem 2006, 98:1450-1456.
60. Huang YC, Hung WC: 1,25-dihydroxyvitamin D3 transcriptionally
represses p45Skp2 expression via the Sp1 sites in human prostate
cancer cells. J Cell Physiol 2006, 209:363-369.
61. McGaffin KR, Chrysogelos SA: Identification and characterization of a
response element in the EGFR promoter that mediates transcriptional
repression by 1,25-dihydroxyvitamin D3 in breast cancer cells. J Mol
Endocrinol 2005, 35:117-133.
62. Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, et al:
miR-21: an androgen receptor-regulated microRNA that promotes
hormone-dependent and hormone-independent prostate cancer
growth. Cancer Res 2009, 69:7165-7169.
63. Xiong J, Du Q, Liang Z: Tumor-suppressive microRNA-22 inhibits the
transcription of E-box-containing c-Myc target genes by silencing c-Myc
binding protein. Oncogene 2010, 29:4980-4988.
64. Boominathan L: The tumor suppressors p53, p63, and p73 are regulators
of microRNA processing complex. PLoS One 2010, 5:e10615.
65. Frankel LB, Christoffersen NR, Jacobsen A, Lindow M, Krogh A, Lund AH:
Programmed cell death 4 (PDCD4) is an important functional target of
the microRNA miR-21 in breast cancer cells. J Biol Chem 2008,
283:1026-1033.
66. Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, et al:
Vitamin D deficiency and insufficiency among patients with prostate
cancer. BJU Int 2009, 104:909-914.
67. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using
real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods
2001, 25:402-408.
68. Huang dW, Sherman BT, Lempicki RA: Systematic and integrative analysis
of large gene lists using DAVID bioinformatics resources. Nat Protoc
2009, 4:44-57.
doi:10.1186/1476-4598-10-58
Cite this article as: Wang et al.: Effects of 1a,25 dihydroxyvitamin D3
and testosterone on miRNA and mRNA expression in LNCaP cells.
Molecular Cancer 2011 10:58.
Wang et al. Molecular Cancer 2011, 10:58
http://www.molecular-cancer.com/content/10/1/58
Page 15 of 15